Search
Inhibikase Therapeutics Inc
IKTAdd to Watchlist
1.990USD
+0.050+2.58%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
262.74MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.58%
5 Days
+4.19%
1 Month
+19.88%
6 Months
+2.05%
Year to Date
-2.93%
1 Year
+5.29%
Key Figures
1.970Open
2.040High
679.00KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.51%Turnover Ratio
1.940Prev. Close
1.950Low
977.20KTurnover
LossP/E Static
1.57P/B
0.00%Div Yield TTM
-38.09%ROA
2.26052wk High
0.77Volume Ratio
-27.52MNet Profit
132.03MShares
-0.4332EPS TTM
0.94Beta
-40.23%ROE
1.33052wk Low
4.64%Amplitude
100.00%Gross Margin
262.74MMarket Cap
4.11Reward/Risk
4.11%Risk Rate
TradingKey Stock Score of Inhibikase Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Inhibikase Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 93 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.88.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Inhibikase Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Inhibikase Therapeutics Inc Highlights
StrengthsRisks
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -4.59, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 103.21M shares, increasing 29.82% quarter-over-quarter.
Held by Frank Sands
Star Investor Frank Sands holds 12.86M shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
5.875
Target Price
+202.84%
Upside Space
Inhibikase Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Inhibikase Therapeutics Inc Info
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Ticker SymbolIKT
CompanyInhibikase Therapeutics Inc
CEOIwicki (Mark T)
Websitehttps://www.inhibikase.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Inhibikase Therapeutics Inc (IKT)?
The current price of Inhibikase Therapeutics Inc (IKT) is 1.99.
What is the symbol of Inhibikase Therapeutics Inc?
The ticker symbol of Inhibikase Therapeutics Inc is IKT.
What is the 52-week high of Inhibikase Therapeutics Inc?
The 52-week high of Inhibikase Therapeutics Inc is 2.26.
What is the 52-week low of Inhibikase Therapeutics Inc?
The 52-week low of Inhibikase Therapeutics Inc is 1.33.
What is the market capitalization of Inhibikase Therapeutics Inc?
The market capitalization of Inhibikase Therapeutics Inc is 262.74M.
Is Inhibikase Therapeutics Inc (IKT) currently rated as Buy, Hold, or Sell?
According to analysts, Inhibikase Therapeutics Inc (IKT) has an overall rating of Buy, with a price target of 5.88.
What is the Earnings Per Share (EPS TTM) of Inhibikase Therapeutics Inc (IKT)?
The Earnings Per Share (EPS TTM) of Inhibikase Therapeutics Inc (IKT) is -0.49.